Ermium Therapeutics at BIO-Europe Fall 2021
Ermium Therapeutics is participating to BIO-Europe Fall 2021 meeting and its partnering sessions
Ermium Therapeutics is participating to BIO-Europe Fall 2021 meeting and its partnering sessions
Besides the already published in vitro and vivo proof of concept data, Ermium established, with a proprietary CXCR4-targeted non antagonist immunomodulator, proof of concept in three in vivo models, including in a well-known murine disease model of systemic lupus erythematosus.
Ermium Therapeutics © 2024 All Rights Reserved
Design by Cédric Adam